In another sign of the intense interest in the category of presbyopia-correcting drops, Visus Therapeutics raised $36 million in Series A financing that will be used to advance its Brimochol clinical development program. The company’s lead asset is a proprietary combination of the cholinergic agent carbachol plus the alpha-2 agonist brimonidine, both Food and Drug Administration-approved, well-studied agents that work together to mitigate presbyopia by producing a “pinhole” or small-aperture effect that can last at least eight hours.